Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Tirzepatide (Mounjaro/Zepbound) and Semaglutide (Ozempic/Wegovy) are the interventions that have demonstrated clinically meaningful, sustained fat reduction across large patient populations
"We might find some real problems if we are not monitoring the body composition, especially for the older patients," Ahmed says
It is recommended not to use orlistat in women who are breastfeeding
An analysis of insurance claims for GLP-1 weight-loss therapy (in patients without diabetes) found only 29% were still on the medication at 1 year, and a mere 15% at 2 years (source)
The Medicare GLP-1 Bridge specifically covers the weight management indications, so Ozempic and Mounjaro are not part of the bridge program
